InvestorsHub Logo
Followers 165
Posts 19872
Boards Moderated 2
Alias Born 12/09/2004

Re: Gator328 post# 204029

Wednesday, 07/31/2019 10:46:20 PM

Wednesday, July 31, 2019 10:46:20 PM

Post# of 463672

Today's news is nice but it seems a bit unnecessary because everyone knew Anavex was safe from the P2A trials.



If everyone knew 2-73 was safe then the FDA wouldn't have wanted the safety trial in the first place.

What we know is that 2-73 had very mild toxicity issues in the elderly population diagnosed with AD.

The much younger population of girls with Rett syndrome have a whole host of issues related to the brain chemistry problems caused by the mutated gene. These girls have developmental issues that AD subjects do not just to mention one big difference.

The safety trial is needed on the older Rett patients to establish a probability that 2-73 will not cause obvious problems for the younger, still developing Rett girls that could be vulnerable to things that mature individuals would not be subject to.

The young girls still have developing brains and bodies that offer many more opportunities for things to go wrong.
Volume:
Day Range:
Bid:
Ask:
Last Trade Time:
Total Trades:
  • 1D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
Recent AVXL News